Headquartered in Princeton, NJ Fiscal year ends December NASDAQ: PMVP pmvpharma.com
PMV Pharmaceuticals is a clinical-stage precision oncology company focused on the discovery and development of small molecule therapies targeting p53, a tumor suppressor protein mutated in approximately half of all cancers. The company's lead product candidate, rezatapopt (PC14586), is a first-in-class small molecule p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring wild-type tumor-suppressor function. Rezatapopt is being evaluated in the Phase 1/2 PYNNACLE clinical trial across multiple tumor types including ovarian, lung, breast, and endometrial cancers. The company has received FDA Fast Track designation and Orphan Drug Designation for rezatapopt. PMV Pharma was co-founded by Dr. Arnold Levine, who discovered the p53 protein in 1979, and the company leverages over four decades of p53 biology research. PMV Pharma is pre-revenue and trades on Nasdaq under the ticker PMVP. Updated
Do you have $1,500 you’d like to use to try investing in penny stocks? Some investments in the category can yield outsized gains. But you need to be aware of the risks…
A quiet week so far with markets trading slightly higher and analyst ratings trickling in. Just enough action to keep investors interested.
PMV Pharmaceuticals is a clinical-stage precision oncology company focused on the discovery and development of small molecule therapies targeting p53, a tumor suppressor protein mutated in approximately half of all cancers.
The Wall Street consensus 12-month price target for PMVP is $4.20.
